RecruitingRecruiting
A Study to Evaluate Efficacy and Safety of IBI112 in Adolescent Participants With Moderate to Severe Plaque Psoriasis
NCT07265284 · Innovent Biopharmaceutical Technology (Hangzhou) Co., LTD.
In plain English
Click the button to translate this study into plain language — what it is, who qualifies, and what participation looks like.
Official title
A Phase Ⅰ/Ⅲ Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Picankibart in Adolescent Patients With Moderate to Severe Plaque Psoriasis
About this study
The purpose of this study is to evaluate the efficacy and safety of IBI112 in the treatment of adolescent participants with moderate to severe plaque-type psoriasis.
Eligibility criteria
Inclusion Criteria:
Males or females aged 12 to 18 years; Diagnosed with plaque psoriasis and a history of psoriasis ≥6 months; suitable for phototherapy and/or systemic treatment for psoriasis.
Exclusion Criteria:
History of or current signs or symptoms of severe, progressive, or uncontrolled renal, hepatic, hematological, gastrointestinal, endocrine, pulmonary, cardiac, neurologic, cerebral, or psychiatric disease Participant has history of erythrodermic psoriasis, generalized or localized pustular psoriasis, medication-induced or medication-exacerbated psoriasis, or new onset guttate psoriasis Has received any therapeutic agent directly targeted to IL-17within 6 months of the first administration of study agent Has received any therapeutic agent directly targeted toTNF-a within 3 months of the first administration of study agent Has received any conventional therapeutic agent within 1 months of the first administration of study agent Has received any topic therapeutic agent within 2 weeks of the first administration of study agent Hsa received IBI112
Study design
Enrollment target: 104 participants
Allocation: randomized
Masking: quadruple
Age groups: child, adult
Timeline
Starts: 2025-12-03
Estimated completion: 2029-01-31
Last updated: 2025-12-22
Interventions
Drug: IBI112Drug: placebo
Primary outcomes
- • Percentage of patients achieving Psoriasis Area and severity index(PASI) 75 at week 16 (week 16)
- • Percentage of patients achieving an static Physician's Global Assessment (sPGA) Score of Cleared (0) or Minimal (1) at Week 16 (week 16)
Sponsor
Innovent Biopharmaceutical Technology (Hangzhou) Co., LTD. · industry
Contacts & investigators
ContactBingjing Feng · contact · bingjing.feng@innoventbio.com · +86 18361923769
All locations (1)
Beijing Children's Hospital Affiliated to Capital Medical UniversityRecruiting
Beijing, Beijing Municipality, China